NCT02459236 - A Study of Intermittent Doses of CERC-301 in MDD | Biotech Hunter

Enrollment

115

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions

Major Depressive Disorder

Interventions

DRUG

CERC-301

CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist

DRUG

Placebo

Trial Locations (13)

10128

The Medical Research Network, LLC, New York

10312

Richmond Behavioral Associates, Staten Island

10549

Bioscience Research LLC, Mount Kisco

14618

Fingerlakes Clinical Research, Rochester

18104

Lehigh Center for Clinical Research, Allentown

30005

Institute for Advanced Medical Research, Alpharetta

38119

Research Strategies of Memphis, LLC, Memphis

60169

Alexian Brothers Center for Psychiatric Research, Hoffman Estates

60634

Chicago Research Center, Inc., Chicago

63368

Psychiatric Care and Research Center, O'Fallon

92660

Pharmacology Research Institute (PRI), Newport Beach

97201

Summit Research Network (Oregon) Inc., Portland

98007

Northwest Clinical Research Center, Bellevue